Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Business Wire

03-13

SAN DIEGO, March 13, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37^th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.

The fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting.

Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

For more information on Revelation, please visit www.RevBiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250313776522/en/

Contacts

Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2519889594"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519889594\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2519889594?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-13 18:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2519889594","market":"us","top_or_hot":-1,"title":"Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"315\" src=\"https://s.yimg.com/uu/api/res/1.2/w.PbJALb2GeoISXvMaOUZQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/be3324c255889e6a0b77c5e8fbe08087\" title=\"\" width=\"780\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>SAN DIEGO, March 13, 2025</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences, Inc.</a> (NASDAQ: REVB) (the \"Company\" or \"Revelation\"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37<sup>th</sup> Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.</p>\n<p>The fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting.</p>\n<p>Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.</p>\n<p><b>About <a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences, Inc.</a></b></p>\n<p><a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences, Inc.</a> is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.</p>\n<p>For more information on Revelation, please visit www.RevBiosciences.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250313776522/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Company Contacts </b><br/>Mike Porter<br/><i>Investor Relations </i><br/>Porter LeVay &amp; Rose Inc.<br/>Email: mike@plrinvest.com <br/><br/>Chester Zygmont, III<br/><i>Chief Financial Officer </i><br/>Revelation Biosciences Inc.<br/>Email: czygmont@revbiosciences.com<br/><br/><br/><br/><br/><br/><br/><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2025-03-13 18:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body>\n<figure>\n<img border=\"0\" height=\"315\" src=\"https://s.yimg.com/uu/api/res/1.2/w.PbJALb2GeoISXvMaOUZQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/be3324c255889e6a0b77c5e8fbe08087\" title=\"\" width=\"780\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>SAN DIEGO, March 13, 2025</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences, Inc.</a> (NASDAQ: REVB) (the \"Company\" or \"Revelation\"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37<sup>th</sup> Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.</p>\n<p>The fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting.</p>\n<p>Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.</p>\n<p><b>About <a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences, Inc.</a></b></p>\n<p><a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences, Inc.</a> is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.</p>\n<p>For more information on Revelation, please visit www.RevBiosciences.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250313776522/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Company Contacts </b><br/>Mike Porter<br/><i>Investor Relations </i><br/>Porter LeVay &amp; Rose Inc.<br/>Email: mike@plrinvest.com <br/><br/>Chester Zygmont, III<br/><i>Chief Financial Officer </i><br/>Revelation Biosciences Inc.<br/>Email: czygmont@revbiosciences.com<br/><br/><br/><br/><br/><br/><br/><br/><br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/revelation-biosciences-host-fireside-chat-100000585.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4218","symbol_name":"酒店及度假村房地產信託","start_time":0,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-host-fireside-chat-100000585.html","article_id":"2519889594","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519889594","pubTimestamp":1741860000,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN DIEGO, March 13, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.Company Contacts Mike PorterInvestor Relations Porter LeVay & Rose Inc.Email: mike@pl","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4218":"酒店及度假村房地产信托","REVBW":"Revelation Biosciences, Inc.","HST":"美国豪斯特酒店","REVB":"Revelation Biosciences, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4181":"酒店及度假村房地产投资信托"},"translate_title":"Revelation Biosciences将在第37届罗斯年会上举办炉边谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HST":1,"REVB":1,"REVBW":0.9},"content_text":"SAN DIEGO, March 13, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the \"Company\" or \"Revelation\"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.\nThe fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting.\nInvestors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.\nAbout Revelation Biosciences, Inc.\nRevelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.\nFor more information on Revelation, please visit www.RevBiosciences.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250313776522/en/\nContacts\nCompany Contacts Mike PorterInvestor Relations Porter LeVay & Rose Inc.Email: mike@plrinvest.com Chester Zygmont, IIIChief Financial Officer Revelation Biosciences Inc.Email: czygmont@revbiosciences.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1}}}